Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C virus replicons: potential role for drug development.

Ralf Bartenschlager1

  • 1Department of Molecular Virology, Institute of Hygiene, University of Heidelberg, Otto-Meyerhof-Zentrum, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany. ralf_bartenschlager@med.uni-heidelberg.de

Nature Reviews. Drug Discovery
|November 5, 2002
PubMed
Summary

Developing causal therapies requires methods to test compound inhibition. A new hepatitis C virus replicon system offers a promising approach for antiviral drug discovery, overcoming previous propagation challenges.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.

Cell reports·2026
Same author

Renewed momentum for HCV and HCC research.

Journal of hepatology·2026
Same author

ProTides for Antiviral Activity Beyond Liver Cells.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Correction: RBM39 shapes innate immunity by controlling expression of key factors of the interferon response.

Frontiers in immunology·2026
Same author

CDK8 and CDK19 Mediator kinases are required for hepatitis delta virus replication.

Hepatology (Baltimore, Md.)·2026
Same author

Reconstitution of interferon regulatory factor 7 expression restores interferon beta induction in Huh7 cells.

Journal of virology·2025

Area of Science:

  • Virology
  • Hepatology
  • Drug Discovery

Background:

  • Causal therapies require systems to assess compound inhibitory capacity.
  • Antiviral drug efficacy is typically evaluated in cell-culture systems.
  • Hepatitis C virus (HCV) propagation in the lab has been inefficient, hindering drug development.

Purpose of the Study:

  • To highlight the significance of developing systems for assessing antiviral compound efficacy.
  • To introduce the hepatitis C virus replicon system as a novel tool for drug discovery.

Main Methods:

  • The abstract does not specify methods but refers to the development of a replicon system.

Main Results:

  • The development of a hepatitis C virus replicon system has been achieved.

Related Experiment Videos

  • This system presents a new possibility for discovering antiviral drugs.

    • Conclusions:

    • The hepatitis C virus replicon system is a significant advancement for antiviral drug discovery.
    • This system addresses the challenge of inefficient HCV propagation in laboratory settings.